Vivani medical director Williams buys shares worth $2.4m

Published 17/09/2025, 15:02
Vivani medical director Williams buys shares worth $2.4m

Director Gregg Williams of Vivani Medical, Inc. (NASDAQ:VANI) acquired a total of 2,068,453 shares of common stock on September 15, 2025, in a series of transactions. The prices for these purchases ranged from $1.12 to $1.26. The stock, currently trading at $1.42, has shown significant volatility according to InvestingPro data, with a 52-week range of $0.91 to $1.80.

Williams purchased 1,473,215 shares at $1.12, for a total value of $1,650,000. Additionally, he acquired 595,238 shares at $1.26, totaling $749,999. With a market capitalization of $84.1 million and analysts setting a $4.00 price target, this insider purchase comes as InvestingPro analysis indicates the company is rapidly burning through cash. Get access to 5 more exclusive ProTips and detailed financial metrics with InvestingPro.

Following these transactions, Williams directly owns 4,799,200 shares and indirectly owns 15,909,348 shares of Vivani Medical, Inc. common stock.

In other recent news, Vivani Medical announced plans to begin a Phase 1 clinical trial for its semaglutide implant, NPM-139, aimed at chronic weight management. The trial is expected to commence in the first half of 2026, pending regulatory approval. Additionally, Vivani Medical has secured $10 million in equity financing to further develop the semaglutide implant. This funding, which involves an investment from an entity owned by the company’s Chairman Gregg Williams, ensures financial stability through the latter half of 2026. H.C. Wainwright has maintained a Buy rating on Vivani Medical, setting a price target of $4.00, following the announcement of these clinical development plans. The firm highlighted the potential of the semaglutide implant in addressing obesity and related comorbidities. In other developments, Vivani Medical’s shareholders elected all six board nominees during the company’s 2025 Annual Meeting of Stockholders. This meeting saw 37,097,099 shares represented, establishing a quorum for decision-making.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.